Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EXELIXIS, INC.

(EXEL)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/12/2021 04/13/2021 04/14/2021 04/15/2021 04/16/2021 Date
23.03(c) 23.42(c) 24.05(c) 23.95(c) 23.59(c) Last
2 054 252 959 469 1 544 582 1 161 575 1 717 519 Volume
-0.39% +1.69% +2.69% -0.42% -1.50% Change
More quotes
Financials (USD)
Sales 2021 1 221 M - -
Net income 2021 108 M - -
Net cash position 2021 1 499 M - -
P/E ratio 2021 69,7x
Yield 2021 -
Sales 2022 1 625 M - -
Net income 2022 320 M - -
Net cash position 2022 1 889 M - -
P/E ratio 2022 23,9x
Yield 2022 -
Capitalization 7 386 M 7 386 M -
EV / Sales 2021 4,82x
EV / Sales 2022 3,38x
Nbr of Employees 773
Free-Float 98,1%
More Financials
Company
Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ... 
More about the company
Notations Surperformance© of Exelixis, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about EXELIXIS, INC.
04/14BRISTOL MYERS SQUIBB  : Gets European Nod for Opdivo Combo as First-Line Treatme..
MT
04/05EXELIXIS  : Gets FDA Go-Ahead to Test XB002 in Advanced Solid Tumors
MT
04/05EXELIXIS  : Announces U.S. FDA Accepts Investigational New Drug Application for ..
BU
04/01EXELIXIS'  : Partner Ipsen Receives European Commission Approval for CABOMETYX (..
AQ
04/01ROYALTY PHARMA  : Acquires Royalty Stake on Two GlaxoSmithKline Cancer Drugs
MT
04/01Royalty Pharma Acquires Royalty Interest in Cabometyx and Cometriq from GSK
DJ
03/31EXELIXIS  : Credit Suisse Starts Exelixis at Outperform with $30 Price Target
MT
03/31EXELIXIS  : Announces Enrollment Completion in Phase 3 COSMIC-313 Pivotal Trial ..
AQ
03/31EXELIXIS  : Says Partner Ipsen Gets Regulatory Nod for Use of Cabometyx With Opd..
MT
03/31EXELIXIS  : rsquo; Partner Ipsen Receives European Commission Approval for CABOM..
BU
03/30EXELIXIS  : Completes Enrollment in Phase 3 Trial of Cabozantinib Combination to..
MT
03/30EXELIXIS  : Announces Enrollment Completion in Phase 3 COSMIC-313 Pivotal Trial ..
BU
03/18EXELIXIS  : Working With Merck KGaA, Pfizer, Darmstadt, Germany to Expand Ongoin..
MT
03/18Exelixis In Collaboration and Supply Agreement with Merck KGaA and Pfizer
DJ
03/18EXELIXIS  : Announces Clinical Trial Collaboration and Supply Agreement with Mer..
BU
More news
News in other languages on EXELIXIS, INC.
2020Floride, vaccin et Fed au menu
2020EN DIRECT DES MARCHES : Airbus, Ipsen, Alstom, Flatex, Tesla, Soitec, Biophyt..
2020IPSEN  : collaboration clinique pour le cabozantinib
2020Ipsen s'allie à Exelixis et Roche pour développer son médicament Cabometyx
2018STOCK MARKET PARIS : "Tariff Man" a encore frappé
More news
Analyst Recommendations on EXELIXIS, INC.
More recommendations
Chart EXELIXIS, INC.
Duration : Period :
Exelixis, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXELIXIS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 15
Average target price 31,29 $
Last Close Price 23,59 $
Spread / Highest target 56,8%
Spread / Average Target 32,6%
Spread / Lowest Target 10,2%
EPS Revisions
Managers and Directors
NameTitle
Michael M. Morrissey President, Chief Executive Officer & Director
Christopher J. Senner Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Chairman
Gisela M. Schwab Chief Medical Officer & President-Medical Affairs
Peter Lamb Chief Scientific Officer & EVP-Scientific Strategy
Sector and Competitors
1st jan.Capitalization (M$)
EXELIXIS, INC.17.54%7 472
GILEAD SCIENCES, INC.12.08%82 808
VERTEX PHARMACEUTICALS INCORPORATED-6.45%57 225
REGENERON PHARMACEUTICALS, INC.-0.40%51 514
WUXI APPTEC CO., LTD.-0.05%50 406
BIONTECH SE72.62%33 987